Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily inhaled molgramostim in adult subjects with autoimmune pulmonary alveolar proteinosis
2020-001263-85Phase 3Completed
- Sponsor
- Savara
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune pulmonary alveolar proteinosis (aPAP) and pulmonary alveolar proteinosis (PAP) comparing Molgramostim 300 µg nebulizer solution with Placebo nebulizer solution (2 arms). Primary endpoint: Change in % predicted DLCO from baseline to Week 24. Started Oct 2020; status: completed.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on 2020-001263-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001263-85.